Market closedNon-fractional
uniQure/QURE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Ticker
QURE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Amsterdam, Netherlands
Employees
480
Website
www.uniqure.com
uniQure Metrics
BasicAdvanced
$190M
Market cap
-
P/E ratio
-$6.20
EPS
0.98
Beta
-
Dividend rate
Price and volume
Market cap
$190M
Beta
0.98
Financial strength
Current ratio
9.39
Quick ratio
8.923
Long term debt to equity
364.216
Total debt to equity
369.665
Interest coverage (TTM)
-4.58%
Management effectiveness
Return on assets (TTM)
-22.03%
Return on equity (TTM)
-106.11%
Valuation
Price to revenue (TTM)
9.857
Price to book
1.28
Price to tangible book (TTM)
3.04
Price to free cash flow (TTM)
-1.384
Growth
Revenue change (TTM)
-82.73%
Earnings per share change (TTM)
84.97%
3-year revenue growth
-20.53%
3-year earnings per share growth
26.05%
What the Analysts think about uniQure
Analyst Ratings
Majority rating from 13 analysts.
uniQure Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.4M
27.27%
Net income
-$66M
-10.38%
Profit margin
-780.95%
-29.59%
uniQure Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.44
-$1.88
-$1.53
-$1.36
-
Expected
$2.05
-$0.85
-$1.46
-$1.28
-$1.25
Surprise
-170.23%
121.38%
5.20%
6.25%
-
uniQure News
AllArticlesVideos
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
PRNewsWire·5 days ago
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
GlobeNewsWire·5 days ago
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $190M as of July 06, 2024.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of July 06, 2024.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell uniQure stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.